Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, FiscalAI reports.
Matinas Biopharma Trading Down 4.7%
MTNB stock traded down $0.01 during midday trading on Friday, hitting $0.22. 526,103 shares of the company’s stock were exchanged, compared to its average volume of 2,155,485. Matinas Biopharma has a 1-year low of $0.22 and a 1-year high of $3.09. The stock has a market capitalization of $1.42 million, a PE ratio of -0.11 and a beta of 1.76. The business has a 50-day simple moving average of $0.50 and a two-hundred day simple moving average of $0.57.
Hedge Funds Weigh In On Matinas Biopharma
An institutional investor recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC bought a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent reporting period. 11.77% of the stock is currently owned by institutional investors and hedge funds.
Matinas Biopharma Company Profile
Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.
The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.
Read More
- Five stocks we like better than Matinas Biopharma
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
